Emergent BioSolutions Inc. company info

CIK 1367644
IRS Number 141902018
State of incorporation DE
Business address 400 PROFESSIONAL DR, SUITE 400
Mail address 400 PROFESSIONAL DR, SUITE 400

Short summary

Emergent BioSolutions Inc. is a Maryland company, with head office located at 400 Professional Dr, Suite 400 Gaithersburg, Maryland 20879. The company achieved a record breaking net income last year - 82.59 million USD. This is 59.52% higher than one reported in 2016. In 2017 the company owned a total of 1.14 billion USD worth of assets, including 541.31 million USD worth of current assets. The company amassed the most assets last year, totalling up to 1.14 billion USD. The company net sales last year amounted to 560.87 million USD, which means a 14.75% increase when compared to 2016. The company allocated 97.38 million USD of its income to research and development.

Emergent BioSolutions Inc. Income Statement

Name [in Millions USD]2008200920102011201220132014201520162017Trends
Revenue, Net 234.79286.17273.38281.89312.75450.14489.33488.78560.87
Selling, General and Administrative Expense 73.7976.2174.2876.0287.88108.59121.15143.69143.50
Research and development 74.5989.30124.83120.23119.93104.72154.00108.2997.38
Operating Income (Loss) 40.1573.5632.1029.9742.8058.06141.51105.52124.29
Interest expense 0.01000.0108.246.527.626.59
Other Nonoperating Income (Expense) -0.05-1.02-0.261.970.432.930.150.26-0.82
Income Tax Expense (Benefit) 14.9726.1815.8313.9213.1116.3226.9036.7036.04
Net income 31.1451.7023.0223.5231.1436.7462.8751.7882.59

Emergent BioSolutions Inc. Balance Sheet

Name [in Millions USD]2008200920102011201220132014201520162017Trends
Cash and cash equivalents 91.47102.19122.09161.84156.24168.13214.84333.40315.63190.24
Accounts Receivable, Net, Current 47.2646.8254.3778.2799.7266.75102.51189.49
Inventories 17.2616.0118.5866.0384.7196.6770.53139.37
Deferred income taxes 7.080.641.2601.4800
Property, Plant and Equipment, Gross 241.43284.71321.61393.41469.16507.62571.73
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment 32.4642.9457.3779.43110.13127.38152.58
Goodwill 5.035.505.5047.1952.5954.9041.0049.13
Intangible Assets, Net (Excluding Goodwill) 066.6862.1152.6530.76111.77
Other Assets, Noncurrent 0.710.710.568.777.251.853.724.87
Total assets 493.98527.14555.61837.25943.321,056.47970.481,138.89
Current assets 223.84243.22248.16345.45435.49528.05509.74541.31
Accounts payable 32.1823.3025.7136.9741.8258.9729.6041.63
Taxes Payable, Current 00.12002.77
Total current liabilities 72.5044.4748.7876.4386.96103.8672.9396.81
Long-term Debt, Excluding Current Maturities 29.0758.1456.07251253247.39248.6913.48
Long-term Debt 62.2062.7762
Deferred Revenue, Noncurrent 2.9501.636.088.4117.0917.26
Deferred income taxes 00
Total liabilities 112.75104.62106.53349.48381.07383.79349.88200.55
Common Stock, Value, Issued
Retained Earnings (Accumulated Deficit) 166.66197.67222.81236.32280.85344.18269.58349.78
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.77-3.25-3.51-3.25-3.66-3.08-3.52-4.42

Emergent BioSolutions Inc. Cash Flow

Name [in Millions USD]2008200920102011201220132014201520162017Trends
Net income 31.1451.7023.0223.5231.1436.7462.8751.7882.59
Amortization of Intangible Assets 1.95-
Depreciation and amortization 5.005.999.3611.2018.9622.3424.5028.0232.24
Deferred Income Tax Expense (Benefit) 5.759.2320.193.3813.8616.493.465.193.26
Accounts receivable 30.02-19.0934.8721.89-35.46-21.4164.3522.454.81
Inventories -6.21-0.801.940.50-0.52-4.2311.269.03-6.07
Accounts payable -1.553.392.510.27-0.55-9.284.75-14.7916.13
Deferred revenue -0.01-0.84-10.860.450.032.853.474.6015.02
Net Cash Provided by (Used in) Operating Activities 29.8798.9312.1939.6496.97112.3242.5254.62208.14
Payments to Acquire Property, Plant, and Equipment 33.2922.1054.0353.8542.0230.6744.8176.2654.83
Payments to Acquire Businesses, Net of Cash Acquired 017.870025.87179.380.650195.10
Net Cash Provided by (Used in) Investing Activities -33.29-23.46-53.96-40.11-67.89-210.05-45.46-76.26-249.93
Net Cash Provided by (Used in) Investing Activities, Continuing Operations -67.89-210.05-45.46-76.26
Proceeds from Issuance of Long-term Debt 1200
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 16.0022.9710.3116.6726.5943.7534.4727.95
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 16.0022.9710.3116.6726.5943.7534.4727.95
Payments for Repurchase of Common Stock 005.910.210.200.10033.08
Net Cash Provided by (Used in) Financing Activities 14.84-9.3616.66-1.778.61198.8735.39-19.78-51.40
Cash and Cash Equivalents, Period Increase (Decrease) 11.4566.10-25.12-2.2437.67101.1632.30-41.28-93.22